SunOpta Inc. (NASDAQ:STKL) has risen by 7.77% in below-average trading, after posting results for its third quarter ended October 3. The company’s revenues mildly declined to $306 million during the most recent quarter, compared to $307.9 million from the prior-year period. Adjusted EBITDA was down to $16.8 million, compared to $18.8 million in the same period last year. Earnings from continuing operations jumped to $664,000, compared to a loss of $460,000 in the year-ago period. Meanwhile, earnings attributable to SunOpta Inc. (NASDAQ:STKL) were $314,000, compared to a loss of $384,000 reported a year earlier.
“We had an in-line quarter on an adjusted basis, and we believe performance will improve as we realize the benefits of the foundation we have built. Looking ahead, we are making good progress in our Consumer Products business, the integration of Sunrise Growers and reaping the benefits of the significant investments we have made in future growth,” SunOpta President and CEO Rik Jacobs said.
A total of 15 funds, out of 730 in our database, held 23.80% of the company’s outstanding stock at the end of June.
Glaukos Corp. (NYSE:GKOS), which identifies itself as an ophthalmic medical technology company, jumped 17.27% in active trading after slumping further in losses as it ended the third quarter of 2015. The company’s net sales grew to $19 million in the third quarter this year, but Glaukos booked a net loss of $2.1 million – which widened slightly from the $2.0 net loss the same quarter in 2014. As an outlook, the company said it expects 2015 full-year net sales to be in the range of $70.5 million to $71.5 million.
“Glaukos has delivered another quarter of record performance that demonstrates the momentum building behind our first-in-class iStent technology as an elegant solution for managing intraocular pressure associated with glaucoma,” Glaukos President and CEO Thomas Burns said.
At the end of the second quarter, a total of nine funds among those we follow held 11.40% of the company’s outstanding stock.